Variable temocillin protein binding and pharmacokinetics in different clinical conditions: Implications for target attainment

Letao Li, Perrin Ngougni Pokem, Sebastiaan D.T. Sassen, Xavier Wittebole, Pierre François Laterre, Steven Vervaeke, Markus Zeitlinger, Françoise Van Bambeke, Anouk E. Muller*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Aims: 

The beta-lactam antibiotic temocillin is increasingly used to treat extended-spectrum beta-lactamase (ESBL-producing) strains; however, its protein binding is complex. This study aims to predict unbound temocillin concentrations in various participant groups to determine its impact on the probability of target attainment (PTA) and to improve dosing recommendations. 

Methods: 

The plasma pharmacokinetics were analysed using non-linear mixed-effects modelling. Data from individuals in four groups: healthy volunteers (HV), urinary tract infection patients (UTI), ventriculitis patients and sepsis-ICU patients were included. Simulations were performed to compare the PTA for different dosing regimens and participant-groups. 

Results:

 A two-compartment protein-binding model best fitted the 1085 concentrations (543 unbound, 542 total). Temocillin clearance was influenced by creatinine clearance, serum albumin (ALB) and C-reactive protein (CRP). For 2 g q8h intermittent infusion, the PTAs at an MIC of 16 mg/L were 2.3%, 39.5%, 10.0% and 72.5%, for HV, UTI, ventriculitis and sepsis-ICU patients, respectively. The effects of the covariates on the PTA were simulated for two example patients with intermittent infusion: the PTAs at an MIC of 8 mg/L for a sepsis-ICU patient (CRP 300 mg/L, albumin 15 g/L) and a mild-UTI patient (CRP 30 mg/L, albumin 35 g/L) were 94.3% and 62.4%, respectively. Continuous infusion consistently outperformed intermittent infusion in achieving the desired pharmacodynamic target (time above MIC).

Conclusions: 

Our study underscores the significant variation in temocillin clearance and unbound fractions among different participant groups, challenging the efficacy of traditional 2 g q12h dosing. For patients with enhanced renal function and lower inflammation, continuous infusion emerges as a more effective strategy to achieve optimal target attainment.

Original languageEnglish
JournalBritish Journal of Clinical Pharmacology
DOIs
Publication statusE-pub ahead of print - 22 Jan 2025

Bibliographical note

Publisher Copyright:
© 2025 British Pharmacological Society.

Fingerprint

Dive into the research topics of 'Variable temocillin protein binding and pharmacokinetics in different clinical conditions: Implications for target attainment'. Together they form a unique fingerprint.

Cite this